{"id":16,"date":"2019-04-23T00:02:31","date_gmt":"2019-04-23T00:02:31","guid":{"rendered":"https:\/\/www.cutaquigus.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/"},"modified":"2025-01-29T00:28:34","modified_gmt":"2025-01-29T00:28:34","slug":"ease-of-administration-pharmacokinetics","status":"publish","type":"page","link":"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/","title":{"rendered":"Ease of Cutaquig SCIg Administration &#038; Pharmacokinetics"},"content":{"rendered":"\n<h2>An easy-to-use formulation<\/h2>\n<p class=\"h3\">Low Viscosity Allows for Easy Injectability and Flexible Subcutaneous Administration<sup>1-3<\/sup><\/p>\n<ul class=\"slick arrow-v2\">\n<li><strong>Low<\/strong> mean viscosity: 11.6 (&plusmn; 0.6 )&mdash;Lower than 20% IgG products<\/li>\n<li><strong>Progressive<\/strong> infusion speed<br>\n<table cellpadding=\"0\" cellspacing=\"0\" border=\"0\" class=\"--infusion-chart\" style=\"margin-top: .5em;\">\n<tr>\n<th><\/th>\n<th>Adults<br>&ge;17 years<\/th>\n<th>Children<br>2-16 years<\/th>\n<\/tr>\n<tr>\n<th class=\"bord-rad-top-left\">First 2 Infusions<\/th>\n<td>&le;20 mL\/hour\/site<\/td>\n<td>&le;15 mL\/hour\/site in children<\/td>\n<\/tr>\n<tr>\n<th>Increases in subsequent infusions<\/th>\n<td>10 mL\/hour\/site (as tolerated)<\/td>\n<td>5-10 mL\/hour\/site (as tolerated) in children<\/td>\n<\/tr>\n<tr>\n<th class=\"bord-rad-bottom-left\">Maximum<\/th>\n<td>52 mL\/hour\/site (as tolerated)<\/td>\n<td class=\"bord-rad-bottom-right\">25 mL\/hour\/site (as tolerated) in children<\/td>\n<\/tr>\n<\/table>\n<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/cutaquigusa.com\/hcp\/usage\/\">Find out more about cutaquig administration.<\/a><\/strong><\/p>\n<section id=\"block-1a\" class=\"block block--content alignfull\">\n<div class=\"block__content-wrapper alignwide \">\n<div class=\"aligndefault\">\n<h2>Favorable pharmacokinetics<sup>1,2,4,5<\/sup><\/h2>\n<p>For both adult and pediatric patients 2 years of age and older, total IgG trough levels did not fluctuate during the course of the study, with higher trough levels achieved with cutaquig treatment compared with their previous IVIg<\/p>\n<ul class=\"slick arrow-v2\">\n<li>At the end of the IVIg period, trough levels ranged from 5.0 to 5.1 g\/L<\/li>\n<li>Over the entire SCIg treatment period, individual trough levels of total IgG ranged from 4.4 to 24.0 g\/L<\/li>\n<\/ul>\n<p><small>IgG: immunoglobulin G; IVIg: intravenous immunoglobulin; SCIg: subcutaneous immunoglobulin.<\/small><\/p>\n<\/div>\n<\/div>\n<\/section>\n<section id=\"block-1a\" class=\"block block--content alignfull\">\n<div class=\"block__content-wrapper alignwide \">\n<div class=\"aligndefault\">\n<h3>Once-weekly cutaquig infusions of approximately 161 mg\/kg were:<\/h3>\n<ul class=\"slick arrow-v2\">\n<li>Sufficient to maintain trough IgG levels well above the minimum recommended level of 5-6 g\/l.<\/li>\n<li>Correlated with low infection rates in children and adolescents with PI.<sup>5<\/sup><\/li>\n<\/ul><\/div>\n<\/div>\n<\/section>\n<section id=\"block-1a\" class=\"block block--content alignfull\">\n<div class=\"block__content-wrapper alignwide \">\n<div class=\"aligndefault\">\n<h3>In addition to once-weekly infusions, cutaquig offers a flexible dosing schedule that includes:<\/h3>\n<ul class=\"slick arrow-v2\">\n<li>Daily (2-7 days)<\/li>\n<li>Every other week<\/li>\n<\/ul>\n<p><strong><a href=\"https:\/\/cutaquigusa.com\/hcp\/usage\/\">See Dosage and Administration<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n<\/section>\n<section id=\"block-1a\" class=\"block block--content alignfull\">\n<div class=\"block__content-wrapper alignwide \">\n<div class=\"aligndefault\">\n<h2>Dosing<\/h2>\n<table class=\"table-dosage\" cellpadding=\"0\" cellspacing=\"0\" border=\"0\">\n<tbody>\n<tr>\n<td class=\"no-top-border\" width=\"25%\"><strong>Switching from IVIg<\/strong> to cutaquig<\/td>\n<td><b>Calculate using a conversion factor (1.30):<\/b>\n<ul class=\"division\">\n<li class=\"num\">Previous IVIg dose (in grams) x 1.3<\/li>\n<li class=\"denom\">Number of weeks between IVIg doses<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<tr>\n<td><strong>Switching from other Subcutaneous Immunoglobulin<\/strong> (SCIg)<\/td>\n<td>Dosing should be the same as for previous SCIg.<\/td>\n<\/tr>\n<\/tbody>\n<tfoot>\n<tr class=\"top-set\">\n<td>Flexible dosing schedule includes<\/td>\n<td><strong>Daily (2-7 days), Weekly<\/strong> and <strong>Every Other Week<\/strong><\/td>\n<\/tr>\n<\/tfoot>\n<\/table><\/div>\n<\/div>\n<\/section>\n<section id=\"block-2a\" class=\"block block--content-with-full-image alignfull\" style=\"display: none;\">\n<div class=\"block__content-with-full-image-wrapper alignwide \">\n<div class=\"block__image\">\n      <a href=\"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2019\/04\/Higher-Trough-Levels_v2-page-13-1024x556.jpg\" class=\"enlarge\"><br>\n<img width=\"1024\" height=\"556\" alt=\"Higher Trough Levels\" class=\"block__img loaded\" data-original=\"https:\/\/cutaquigusa.com\/wp-content\/uploads\/sites\/2\/2019\/04\/Higher-Trough-Levels_v2-page-13-1024x556.jpg\"><br>\n<\/a>\n    <\/div>\n<\/div>\n<\/section>\n<section id=\"block-3a\" class=\"block block--factoid alignfull\" style=\"display: none;\">\n<div class=\"block__factoid-wrapper alignwide image-right\">\n<div class=\"block__factoid-content\">\n<h3>There were no patients with IgG trough levels <br>below 5 g\/L for both IVIg and SCIg.<sup>1<\/sup><\/h3>\n<\/div>\n<\/div>\n<\/section>\n<section id=\"block-4a\" class=\"block block--cta-with-wysiwyg-and-image alignfull\">\n<div class=\"alignwide\">\n<div class=\"cta-banner cta-banner--fallback-bg\">\n<div class=\"cta-banner__body\">\n<div class=\"cta-banner__body-inner\">\n<div class=\"cta-banner__icon\">\n            <img data-original=\"https:\/\/cutaquigusa.com\/wp-content\/uploads\/2019\/12\/notepad-pink.png\">\n          <\/div>\n<h3>Learn about cutaquig manufacturing and pathogen safety.<\/h3>\n<p>          <a href=\"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/manufacturing-pathogen-safety\/\" class=\"action action--fa-angle-right\">Learn More <i class=\"fa fa-angle-right\"><\/i><\/a>\n        <\/p><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<section id=\"block-5a\" class=\"block block--content alignfull\">\n<div class=\"block__content-wrapper alignwide \">\n<div class=\"aligndefault\">\n<h5>References:<\/h5>\n<ol>\n<li class=\"small\">Kobayashi RH, Gupta S, Melamed I, et al. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (octanorm [cutaquig<sup>&reg;<\/sup>]) in the Treatment of Patients with Primary Immunodeficiencies. Front Immunol. February 2019 | Volume 10 | Article 40.<\/li>\n<li class=\"small\">Cutaquig Full Prescribing Information. Paramus, NJ: Octapharma; rev October 2021.<\/li>\n<li class=\"small\">Gelbmann N, Zo&#776;chling A, Mersich C et al. Cutaquig, Immunoglobulin (human) subcutaneous 16.5% solution for injection (165 mg\/mL) &ndash; biochemical characterization, pathogen safety and stability. Presented at: 2018 Annual Meeting of the Clinical Immunology Society; Toronto, Canada. Poster Presentation.<\/li>\n<li class=\"small\">Octapharma, Data on File.<\/li>\n<li class=\"small\">Kobayashi RH, et al. Immunotherapy. 2021;13(10):813&ndash;824.<\/li>\n<\/ol><\/div>\n<\/div>\n<\/section>\n\n","protected":false},"excerpt":{"rendered":"<p>An easy-to-use formulation Low Viscosity Allows for Easy Injectability and Flexible Subcutaneous Administration1-3 Low mean viscosity: 11.6 (&plusmn; 0.6 )&mdash;Lower&#8230;<\/p>\n","protected":false},"author":29,"featured_media":0,"parent":12,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-16","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ease of Subcutaneous Immunoglobulin Administration | cutaquig\u00ae<\/title>\n<meta name=\"description\" content=\"Learn about the favorable pharmacokinetics of cutaquig\u00ae (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution). Please see Important Safety Info including boxed warning.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ease of Subcutaneous Immunoglobulin Administration | cutaquig\u00ae\" \/>\n<meta property=\"og:description\" content=\"Learn about the favorable pharmacokinetics of cutaquig\u00ae (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution). Please see Important Safety Info including boxed warning.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/\" \/>\n<meta property=\"og:site_name\" content=\"cutaquig\u00ae Healthcare Professionals\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/igcares\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T00:28:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2025\/01\/cutaquig_logo_1200x675.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2025\/01\/cutaquig_logo_1200x675.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":[\"WebPage\",\"MedicalWebPage\"],\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/why-cutaquig\\\/ease-of-administration-pharmacokinetics\\\/\",\"url\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/why-cutaquig\\\/ease-of-administration-pharmacokinetics\\\/\",\"name\":\"Ease of Subcutaneous Immunoglobulin Administration | cutaquig\u00ae\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/why-cutaquig\\\/ease-of-administration-pharmacokinetics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/why-cutaquig\\\/ease-of-administration-pharmacokinetics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cutaquigusa.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2019\\\/04\\\/Higher-Trough-Levels_v2-page-13-1024x556.jpg\",\"datePublished\":\"2019-04-23T00:02:31+00:00\",\"dateModified\":\"2025-01-29T00:28:34+00:00\",\"description\":\"Learn about the favorable pharmacokinetics of cutaquig\u00ae (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution). Please see Important Safety Info including boxed warning.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/why-cutaquig\\\/ease-of-administration-pharmacokinetics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/why-cutaquig\\\/ease-of-administration-pharmacokinetics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/why-cutaquig\\\/ease-of-administration-pharmacokinetics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cutaquigusa.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2019\\\/04\\\/Higher-Trough-Levels_v2-page-13-1024x556.jpg\",\"contentUrl\":\"https:\\\/\\\/cutaquigusa.com\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2019\\\/04\\\/Higher-Trough-Levels_v2-page-13-1024x556.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/why-cutaquig\\\/ease-of-administration-pharmacokinetics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Why cutaquig?\",\"item\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/why-cutaquig\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Ease of Cutaquig SCIg Administration &#038; Pharmacokinetics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/#website\",\"url\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/\",\"name\":\"cutaquig\u00ae Healthcare Professionals\",\"description\":\"Cutaquig\u00ae [Immune Globulin Subcutaneous (Human) - hipp]\",\"publisher\":{\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/#organization\",\"name\":\"Cutaquig\u00ae\",\"url\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/01\\\/cutaquig_logo_696x696.jpg\",\"contentUrl\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/wp-content\\\/uploads\\\/sites\\\/2\\\/2025\\\/01\\\/cutaquig_logo_696x696.jpg\",\"width\":696,\"height\":696,\"caption\":\"Cutaquig\u00ae\"},\"image\":{\"@id\":\"https:\\\/\\\/cutaquigusa.com\\\/hcp\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/igcares\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ease of Subcutaneous Immunoglobulin Administration | cutaquig\u00ae","description":"Learn about the favorable pharmacokinetics of cutaquig\u00ae (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution). Please see Important Safety Info including boxed warning.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/","og_locale":"en_US","og_type":"article","og_title":"Ease of Subcutaneous Immunoglobulin Administration | cutaquig\u00ae","og_description":"Learn about the favorable pharmacokinetics of cutaquig\u00ae (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution). Please see Important Safety Info including boxed warning.","og_url":"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/","og_site_name":"cutaquig\u00ae Healthcare Professionals","article_publisher":"https:\/\/www.facebook.com\/igcares","article_modified_time":"2025-01-29T00:28:34+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2025\/01\/cutaquig_logo_1200x675.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_image":"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2025\/01\/cutaquig_logo_1200x675.jpg","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","MedicalWebPage"],"@id":"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/","url":"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/","name":"Ease of Subcutaneous Immunoglobulin Administration | cutaquig\u00ae","isPartOf":{"@id":"https:\/\/cutaquigusa.com\/hcp\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/#primaryimage"},"image":{"@id":"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/#primaryimage"},"thumbnailUrl":"https:\/\/cutaquigusa.com\/wp-content\/uploads\/sites\/2\/2019\/04\/Higher-Trough-Levels_v2-page-13-1024x556.jpg","datePublished":"2019-04-23T00:02:31+00:00","dateModified":"2025-01-29T00:28:34+00:00","description":"Learn about the favorable pharmacokinetics of cutaquig\u00ae (Immune Globulin Subcutaneous [Human]-hipp, 16.5% solution). Please see Important Safety Info including boxed warning.","breadcrumb":{"@id":"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/#primaryimage","url":"https:\/\/cutaquigusa.com\/wp-content\/uploads\/sites\/2\/2019\/04\/Higher-Trough-Levels_v2-page-13-1024x556.jpg","contentUrl":"https:\/\/cutaquigusa.com\/wp-content\/uploads\/sites\/2\/2019\/04\/Higher-Trough-Levels_v2-page-13-1024x556.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/ease-of-administration-pharmacokinetics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cutaquigusa.com\/hcp\/"},{"@type":"ListItem","position":2,"name":"Why cutaquig?","item":"https:\/\/cutaquigusa.com\/hcp\/why-cutaquig\/"},{"@type":"ListItem","position":3,"name":"Ease of Cutaquig SCIg Administration &#038; Pharmacokinetics"}]},{"@type":"WebSite","@id":"https:\/\/cutaquigusa.com\/hcp\/#website","url":"https:\/\/cutaquigusa.com\/hcp\/","name":"cutaquig\u00ae Healthcare Professionals","description":"Cutaquig\u00ae [Immune Globulin Subcutaneous (Human) - hipp]","publisher":{"@id":"https:\/\/cutaquigusa.com\/hcp\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cutaquigusa.com\/hcp\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cutaquigusa.com\/hcp\/#organization","name":"Cutaquig\u00ae","url":"https:\/\/cutaquigusa.com\/hcp\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cutaquigusa.com\/hcp\/#\/schema\/logo\/image\/","url":"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2025\/01\/cutaquig_logo_696x696.jpg","contentUrl":"https:\/\/cutaquigusa.com\/hcp\/wp-content\/uploads\/sites\/2\/2025\/01\/cutaquig_logo_696x696.jpg","width":696,"height":696,"caption":"Cutaquig\u00ae"},"image":{"@id":"https:\/\/cutaquigusa.com\/hcp\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/igcares"]}]}},"_links":{"self":[{"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/pages\/16","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/comments?post=16"}],"version-history":[{"count":0,"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/pages\/16\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/pages\/12"}],"wp:attachment":[{"href":"https:\/\/cutaquigusa.com\/hcp\/wp-json\/wp\/v2\/media?parent=16"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}